Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition

<p>Supplementary Table S2</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Yufang Bao (15386826) (author)
Drugi avtorji:	Sirui Zhang (15386829) (author), Xiaoyu Zhang (15386832) (author), Yunjian Pan (15386835) (author), Yueren Yan (15386838) (author), Ning Wang (15386841) (author), Yunpeng Ren (15386844) (author), Ji Zuo (15386847) (author), Wei-Xing Zong (15386850) (author), Zefeng Wang (15386853) (author), Yongbo Wang (15386856) (author)
Izdano:	2025
Teme:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Sequence analysis Drug Resistance Regulation of gene expression in drug resistance Reversal of drug resistance Gene Regulation Posttranscriptional and translational control Lung Cancer Oncogenes & Tumor Suppressors Tumor suppressor genes Preclinical Models Animal models of cancer
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Izdano: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
od: Jiachun Su (16990970)
Izdano: (2025)

Supplementary File 2 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
od: Charles Blatti (15292859)
Izdano: (2025)

Supplementary File 3 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
od: Charles Blatti (15292859)
Izdano: (2025)

Supplementary File 4 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
od: Charles Blatti (15292859)
Izdano: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
od: Namhee Kim (14963603)
Izdano: (2025)

Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
od: Namhee Kim (14963603)
Izdano: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_gt0i4ht9264n4a438bvkdrstek